



PATENT
ATTORNEY DOCKET NO. 50274/007002

Certificate of Mailing: Date of Deposit: August 26, 2004

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Janet D'Annunzio-Ellis
Printed name of person mailing correspondence

Janet D'Annunzio-Ellis
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Heinz Peter Vollmers et al. Art Unit: 1642
Serial No.: 09/469,606 Examiner: Alana M. Harris
Filed: December 22, 1999 Customer No.: 21559
Title: SUBSTANCE FOR OBTAINING HIGHLY EFFECTIVE TUMOR
MEDICATIONS AS WELL AS A PROCESS

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.


Pursuant to 37 C.F.R. § 1.97(b)(4), this statement is being filed before the mailing of a first Office action after the filing of a Request for Continued Examination under 37 C.F.R. § 1.114.

Applicants note that an Information Disclosure Statement and a Form PTO-1449 were filed in this case on January 22, 2004, and that they have not yet received an initialed copy of the Form PTO-1449. Applicants thus request an initialed copy of the Form PTO-1449.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 26 August 2004



Kristina Bieker-Brady, Ph.D., P.C.
Reg. No. 39,109

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045

JAN N. TITTER, Ph.D.
Reg. No. 52,290

Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No. 50274/007002		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))				Serial No. 09/469,606		
				Applicant Vollmers et al.		
				Filing Date 12/22/99		
				Group 1642		
				IDS Filed August 26, 2004		
U.S. PATENTS						
Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
	5,763,224	June 9, 1998	Caras et al.			
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	Coyne et al., "Mapping of Epitopes, Glycosylation Sites, and Complement Regulatory Domains in Human Decay Accelerating Factor," <i>J. Immun.</i> , 149(9):2906-2913 (1992).					
	Hara et al., "A Monoclonal Antibody Against Human Decay-Accelerating Factor (DAF, CD55), D17, which Lacks Reactivity with Semen-DAF," <i>Immun. Letters</i> , 37:145-152 (1993).					
	Spendlove et al., "Decay Accelerating Factor (CD55): A Target for Cancer Vaccines?," <i>Cancer Res.</i> , 59:2282-2286 (1999).					
EXAMINER			DATE CONSIDERED			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						